Strategic market access advice, from development to deal.
Advisory boards, portfolio and indication prioritisation, early HTA advice, access due diligence for investors, and training for in-house teams.
Market access risk is set early in development.
Indication, comparator, endpoints and launch markets shape reimbursement years later. Investors often price assets without a clear view of access risk.
Early HTA advice while it can still shape the evidence plan.
We bring the assessor's perspective into development, portfolio and investment decisions: what payers will ask, what they will need and what it means for value and price.
- Which indication should we launch first?
- What is the access risk on this asset?
- What do payers need from our Phase III?
- How do we build HTA capability in-house?
Strategic advisory
Senior judgement when the stakes are high.
- Product advisory boards
- Portfolio and indication prioritisation
- Early HTA and payer advice for development programmes
- Board and leadership briefings on HTA and access risk
- Pipeline reviews: clinical, commercial and health system assessment across a portfolio
- Senior counsel on political and policy risk
Investment advisory
Access risk, priced into the deal.
- Reimbursement and market access due diligence
- Epidemiology-based market sizing and forecasting inputs
- Competitor, comparator and pipeline landscaping
- Pricing benchmarks and HTA outcome analysis
- Market and policy due diligence for investors and private equity
Training and capability building
Bring your team up to speed, fast.
- HEOR and HTA fundamentals for market access, medical and commercial teams
- Hands-on economic modelling training in Excel and R
- Bespoke workshops on NICE, SMC, AWMSG, NCPE, EU JCA and pricing
- Training in costing, MEAL and evaluation methods for NGO and programme staff
Decision tree analysis.
Move the probability of a positive HTA recommendation and the net price. The expected value of each strategy changes, and so does the preferred option.
Illustrative data and models, for demonstration only.
A structured advisory process.
- 01
Brief
The decision, the deadline and what is at stake.
- 02
Diagnose
Evidence, market and access risks reviewed.
- 03
Advise
A clear recommendation, with the reasoning and numbers behind it.
- 04
Equip
Training and tools so your team can carry it forward.
Our analysis on this.
US MFN drug pricing: what it means for UK and European launches
US MFN drug pricing explained: GLOBE, GUARD and GENEROUS, reference baskets, the GDP (PPP) adjuster and what it means for UK, Irish and EU launch prices.
Read the analysisGLP-1s in 2026: the price fell, the access gap did not
HTA and payer decisions for GLP-1 obesity medicines across the US, England, France, Germany and Ireland.
Read the analysisAI in global HTA: where the guidance stands
Only one of eleven major HTA bodies has a full position statement on AI in evidence generation.
Read the analysis“Having someone in the room who understands both how HTA bodies think and the economics behind their decisions made the advisory board far more useful. The advice was practical, and it changed how we planned our evidence generation.”
Client names are withheld at their request for confidentiality.